Polyamino Acid Or Polypeptide With An Uninterrupted Series Of Peptide Repeating Units Patents (Class 930/290)
  • Patent number: 8980326
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: March 17, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
  • Patent number: 7799339
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: September 21, 2010
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
  • Patent number: 7001982
    Abstract: Nonnatural C-linked carbo-?-peptides with robust secondary structures, which involves the synthesis of a new class of ?-peptides called C-linked carbo-?-peptides. The compounds are favorably disposed for the formation of stable helical structures and are useful as biologically active carbo-?-peptides. The new class of ?-peptides have the following formula The new class of ?-peptides are useful as biologically active molecules to disrupt biological interactions of proteins, for molecular design and to synthesize peptide libraries.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: February 21, 2006
    Assignee: Council of Scientific and Industrial Research
    Inventors: Gangavaram Vasantha Madhava Sharma, Kondireddi Ravinder Reddy, Radha Krishna Palakodety, Ajit Chand Kunwar, Ravi Sankar Ampapathi, Jagannadh Bulusu, Jayaprakash Pagadala
  • Patent number: 6908619
    Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: June 21, 2005
    Assignee: University of Saskatchewan
    Inventors: Min Jiang, Andrew A. Potter, Philip Ronald MacLachlan
  • Patent number: 6790448
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: September 14, 2004
    Assignee: The Texas A&M University System University
    Inventors: Yi Xu, Magnus A. O. Hook
  • Publication number: 20020038150
    Abstract: A method for tissue augmentation in a mammal is provided comprising injecting a polymer at a tissue site in need of augmentation and having a tissue temperature, the polymer comprising repeating peptide monomeric units selected from the group consisting of nonapeptide, pentapeptide and tetrapeptide monomeric units, wherein the monomeric units form a series of &bgr;-turns separated by dynamic bridging segments suspended between the &bgr;-turns, wherein the polymer has an inverse temperature transition Tt less than the tissue temperature, and wherein the polymer is injected as a water solution at coacervate concentration in the substantial absence of additional water. A kit containing the injectable bioelastic polymer and a syringe is also provided.
    Type: Application
    Filed: April 18, 2001
    Publication date: March 28, 2002
    Inventor: Dan W. Urry
  • Patent number: 5773574
    Abstract: Novel polypeptides derived from human fibronectin are described which bind to integrin receptors expressed by cells. The receptor binding site of human fibronectin begins at amino acid residue 1394 and ends at residue 1400 of fibronectin. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors, fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: June 30, 1998
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Edward F. Plow, Ronald Bowditch
  • Patent number: 5674977
    Abstract: The invention is a branched synthetic peptide conjugate which can be designed to bind to a target cell surface receptor, to penetrate into target cells, and to deliver a diagnostic probe or cytotoxic functionality to a desired site of action. The invention provides a relatively small molecule of flexible design having a branched structure for systematically incorporating a desired number of cytotoxic functions, peptide-based localization signals or diagnostic probes. The invention addresses problems associated with protein-based therapeutic or diagnostic agents.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: October 7, 1997
    Assignee: The Ontario Cancer Institute
    Inventor: Jean Gariepy
  • Patent number: 5633230
    Abstract: Described herein are anti-cytomegalovirus peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg].sub.9 -NH.sub.2. The use of these peptides, either per se or in combination with other anti-CMV compounds, is disclosed as an effective method for controlling CMV infection.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: May 27, 1997
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Michael Twist, deceased, Martin Sumner-Smith
  • Patent number: 5512660
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: April 30, 1996
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
  • Patent number: 5338724
    Abstract: The present invention provides a composition of matter useful as an antimicrobial agent. This composition of matter comprises at least two polypeptides selected from the group consisting of human polymorphonuclear leukocyte, polypeptides having on apparent molecular weights of about 3,500 daltons, about 13,000 daltons, about 18,000 daltons, about 29,000 daltons, and about 54,000 daltons. The composition of matter has respiratory burst-independent, antimicrobial activity for bacteria and fungi at a pH from about 5.0 to about 8.0 and at calcium ion concentrations up to about 10 mM, bactericidal activity at sodium chloride concentrations up to about 0.3M, and fungicidal activity at sodium chloride concentrations up to about 0.15M. Methods for preparing this composition of matter are also provided.Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
    Type: Grant
    Filed: February 11, 1992
    Date of Patent: August 16, 1994
    Assignees: Cornell Research Foundation, Inc., Rockefeller University
    Inventors: Joelle E. Gabay, Carl E. Nathan
  • Patent number: 5087561
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Michael Chorev, Eliahu Roubini, Ruth F. Nutt, Le T. Duong
  • Patent number: 5087562
    Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 is modified so as to produce HCF analogues which can inhibit the action of HCF.
    Type: Grant
    Filed: April 25, 1990
    Date of Patent: February 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt